

FOR IMMEDIATE RELEASE

Public Relations Contact:

Simona Buergi
503.245.0459 ext. 143

HemCon Medical Technologies Wins Patent Judgment Appeal

PORTLAND, Ore. (September 27, 2011) – HemCon Medical Technologies, Inc. announced today that the U.S. Court of Appeals for the Federal Circuit has delivered their decision which reverses and vacates the judgment from the lower court against HemCon on a patent infringement case brought by Marine Polymer Technologies, Inc. centered around chitosan-based products.

The appellate court reversed the lower court's finding of infringement and vacated the damages award and permanent injunction.

"We are extremely satisfied with this decision from the Court of Appeals" said Nick Hart, President of HemCon. "This vindication of HemCon's actions allows us to focus on continuing to supply our life-saving products to the marketplace."

HemCon announced to its customers last week that it is introducing strategic enhancements to its chitosan-derived product lines, and implementing a modification to its raw material formulation, along with a rebranding of its chitosan-derived products to distinguish itself in the market.

This transition will have no impact on product efficacy, performance, or pricing – HemCon sees this as a brand improvement and supply safeguarding exercise being introduced to the entire HemCon chitosan-derived product line. The initiative will allow HemCon and its partners to further differentiate its hemorrhage control features and antibacterial properties, while providing customers with a continuous supply of product innovation.

HemCon Medical Technologies Inc. (www.hemcon.com) founded in 2001, develops, manufactures, and markets innovative technologies to control bleeding and infection resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital, dental and clinical settings where rapid control of bleeding is of critical importance. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland and the Czech Republic.

###